Today's Rundown Featured Story | | | Friday, February 28, 2020 A year ago, Sangamo’s shares sank after it posted lackluster data for its genome-editing therapy; 12 months down the line, and it’s a complete reversal for the biotech as Biogen lays down a major upfront and biobucks pact for several of its CNS meds. |
|
|---|
|
|  | Download a recent study highlighting the root of key challenges clinical operations professionals are struggling with to complete their oversight responsibilities and the important solutions this study reveals. Read Now >> |
Top Stories Friday, February 28, 2020 A new decade, the same old game: It’s time to play, who will Gilead buy? Sources now says it’s Forty Seven, a cancer-focused startup with a unique MOA. Friday, February 28, 2020 Boehringer Ingelheim has struck a deal with Trutino Biosciences to develop three cytokine therapies. The deal tasks Trutino with applying a platform designed to yield safer, more effective cytokines to the discovery of three oncology drugs for Boehringer. Friday, February 28, 2020 A federal judge has ruled that sponsors need to share results from a decade’s worth of clinical trials. The ruling reflects the judge’s belief that the FDA’s interpretation of the law on clinical trial reporting “is unlawful and must be set aside.” Friday, February 28, 2020 Passage Bio finished 2019 with nearly $160 million in the bank but wasted no time coming back for more, filing earlier this month to raise $125 million in its IPO. Now, the gene therapy player has outraised that goal by $91 million with its $216 million Wall Street debut. Thursday, February 27, 2020 Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer, and has brought on the former global program head of GlaxoSmithKline’s computer-aided drug discovery unit to help run it. Thursday, February 27, 2020 Scientists at the University of Lubeck are targeting a protein-cutting enzyme that many viruses, including the coronavirus COVID-19, need to replicate. They developed a molecule that in cell studies shows potential in blocking coronaviruses, including COVID-19, they reported, and they're planning to move to animal trials soon. Friday, February 28, 2020 Biohaven will challenge much larger companies with its new migraine med Nurtec ODT. But the med scored a strong FDA label and will have a field sales team of more than 500 reps, execs said Friday. On the market, Nurtec ODT will go up against Allergan's Ubrelvy and Eli Lilly's Reyvow, both brand new options, plus older medicines. Thursday, February 27, 2020 In this week's EuroBiotech Report, Bicycle lands Genentech collaboration, GSK inks COVOD-19 adjuvant deal and Grifols buys antibiotic assets. Friday, February 28, 2020 Harvard University and Guangzhou Institute of Respiratory Health, GlaxoSmithKline and Clover Biopharmaceuticals, and Vir Biotechnology and WuXi Biologics have formed R&D collaborations focused on COVID-19. Takeda is buying its celiac disease partner PvP Biologics for $330 million. And more. Friday, February 28, 2020 Pfizer, Mylan vets move over to generics merger Viatris; Spark CMO Reape steps down; Eloxx cuts CEO Ward in shakeup. Resources Sponsored by: Reprints Desk/Research Solutions 3 ways you may be overspending on scientific literature access, and how to fix them. Sponsored by: Eagle Productivity Solutions Mediocre adoption rates aren’t due to poorly designed software or lazy users. They’re the result of how skills are trained. Achieve high adoption rates by implementing the right methodology with a focus on behavior change. Sponsored by: The Kinetix Group Read about the innovative ways payers are making smart moves in the healthcare game. Sponsored by: Veeva Learn how data management teams at ICON, Bioforum, and Vertex Pharmaceuticals are creating the spec and casebook in a single step, reducing study build times and effort by over 50%. Sponsored by: H1 Biopharma companies don't want to go to market with a product no one knows about. H1 has homed in on the often time-consuming research and engagement phases that companies must ace for a successful launch, said Ariel Katz, co-founder of H1. Sponsored by: Clinical Ink Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Accenture Kevin Julian, senior managing director of Accenture’s life sciences practice, recently sat down with FierceBiotech to discuss market trends and Accenture’s new technology platform, INTIENT. Sponsored by: Blue Matter Consulting White paper describing how a biopharma company can successfully differentiate an oncology product when the clinical profile alone is not enough to get the job done. Sponsored by: Medidata To conduct a successful trial, do you need to understand the global eConsent Regulatory landscape? Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. | 
